CT radiomics-based model for predicting TMB and immunotherapy response in non-small cell lung cancer.

"Declarations Ethics approval and consent to participateThis study was approved by the Ethics Committee of Hefei Cancer Hospital, Chinese Academy of Sciences (Approved number: SL-KY2023–080) and was conducted in accordance with the regulations of the Ethics Committee of Hefei Cancer Hospital, Chinese Academy of Sciences. Informed consent was obtained from all recruited patients. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests. "

"Funding This study was supported by the National Natural Science Foundation of China (Grant Number: 81872438), the Program of Research and Development of Key Common Technologies and Engineering of Major Scientific and Technological Achievements in Hefei (Grant Numbers: 2021YL007), the Collaborative Innovation Program of Hefei Science Center, CAS (Grant Numbers: 2022HSC-CIP015), and the Program of Clinical Medical Translational Research in Anhui Province (Grant Numbers: 202304295107020092)."